微芯生物：2025年全年净利润预计同比扭亏

Core Viewpoint - Microchip Biotech is expected to turn a profit in 2025, with a projected net profit of approximately 53.46 million yuan, marking a year-on-year turnaround [1] Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 38.14 million yuan after excluding non-recurring gains and losses for 2025 [1] - Sales revenue from the product Siglecatin Sodium is expected to grow by around 123% year-on-year, driven by its unique clinical value and efforts in self-operated, strategic partnerships, and new retail channels [1] - Sales revenue from the product Sidabamine is projected to increase by approximately 16% year-on-year, supported by the inclusion of a new indication for diffuse large B-cell lymphoma in the National Medical Insurance Directory [1] Market and Product Developments - The clinical value of Sidabamine has received support from the National Healthcare Security Administration and market recognition, contributing to its sales growth [1] - The product Sidabamine was included in the latest version of the National Medical Insurance Directory for regular Class B management in December 2025, which is expected to positively impact sales [1]